Boston Oncology is constructing a product portfolio of the most widely used generic drugs for cancer treatment and other specialty conditions. We are also establishing local manufacturing capabilities for these generics, making them available to populations that cannot always obtain or afford expensive imported drugs.

A generic drug is a copy of a name-brand drug. In general, the innovator of a name-brand drug holds the initial patent for that drug. When the patent expires, other manufacturers may sell generic copies at significantly lower costs. Here are some facts:

  • Generics are just as effective as brand-name drugs.1
  • Generics have the same active ingredients, intended use, dosage, effects, side effects, risks, safety, strength, and route of administration.
  • Generics undergo clinical trials, and they must earn approval from the same regulatory bodies as do name-brand drugs.
  • Generics are much cheaper, because their manufacturers do not bear the start-up costs of developing and marketing the name-brand drug.

Across the globe, we see more and more payers, patients, hospitals, and governments demanding health care that is not only high quality, but cost-effective. This scrutiny makes generic drugs highly attractive, especially in emerging markets where rapidly growing patient populations require expanded service.

Learn more about emerging markets.

(1)Kesselheim et al. Clinical equivalence of generic and brand name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008; 300(21) 2514-2526